Join our webinar: State-of-the-art NGS library quality control solutions

5214_QC_Workflow_0768_700x233 2

Next-generation sequencing (NGS) is revolutionizing life science research and healthcare. The advent of multiple platforms has opened the doors to increased throughput, speed, sensitivity and flexibility, providing researchers with valuable insights at an unprecedented rate.

While recent technological developments have made NGS more accessible to smaller labs, many barriers to implementation still remain. NGS workflows are complex, multistep procedures, and library preparation constitutes one critical step in the workflow. NGS library quality is the single most important determinant of the success of a sequencing run, affecting both the number of reads generated and the validity of the sequence obtained.

Maximize the success of your NGS experiments

Whether you are performing large-scale, genome-wide sequencing studies involving microorganisms, plants or humans, or analyzing rare mutations, exomes and expressions; regardless of the application or model, it is necessary to validate the size distribution, concentration and molarity of the NGS library. Quality control procedures tracking the success of library preparation steps ensure that only high-quality libraries are processed through resource-intensive sequencing runs, saving valuable time, resources and of course your precious sample.

In this upcoming webinar, Dr. Pierre-Henri Ferdinand, Product Manager for QIAxcel systems at QIAGEN, will introduce QC procedures for automated, objective and reliable NGS library preparation, and share his thoughts on how you can bring NGS QC to a new level of convenience and efficiency in your lab.

Date and Time: Wed, Feb 15, 2017 9:30 AM – 10:30 AM EST

Editor’s note: This webinar has ended, but check out the recording here

Abhishek Sharma, Msc., MBA

Senior Global Market Manager, Discovery Sciences

Abhishek Sharma trained as a biochemist and has hands-on experience in nucleic acid and protein purification, tissue culturing and recombinant DNA technology. Previously, he was as a market analyst on emerging technologies in life science research. Sharma also worked in a USA-based healthcare consultancy on the discovery, development and commercialization of new disease treatments across multiple therapeutic areas. Currently, he’s involved with managing QIAGEN’s sample preparation portfolio, specializing in RNA technologies.

Your email address will not be published. Required fields are marked *